KalVista Pharmaceuticals, Inc.
KALV
$13.55
-$0.05-0.37%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -175.87M | -156.39M | -141.77M | -126.64M | -108.30M |
| Total Depreciation and Amortization | 899.00K | 877.00K | 847.00K | 816.00K | 785.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.21M | 19.49M | 21.13M | 21.43M | 11.06M |
| Change in Net Operating Assets | 20.11M | 13.48M | 17.08M | 15.17M | -309.00K |
| Cash from Operations | -127.65M | -122.54M | -102.72M | -89.23M | -96.76M |
| Capital Expenditure | -168.00K | -163.00K | -57.00K | -42.00K | -96.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -31.67M | -46.89M | -67.11M | -84.68M | 35.35M |
| Cash from Investing | -31.83M | -47.05M | -67.17M | -84.72M | 35.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 156.81M | 100.55M | 100.39M | 97.59M | 616.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -333.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 148.35M | 53.12M | 53.12M | 53.12M | 300.00K |
| Cash from Financing | 305.17M | 153.68M | 153.51M | 150.71M | 583.00K |
| Foreign Exchange rate Adjustments | -799.00K | -171.00K | -1.18M | -1.21M | -1.07M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.89M | -16.09M | -17.56M | -24.45M | -61.99M |